Filing Flows › Abeona Therapeutics (ABEO) › Q4 2025
Abeona Therapeutics (ABEO) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 17, 2026
Abeona Therapeutics (ABEO) reported revenue of $5.4M for the fourth quarter 2025 (Q4 2025). Operating margin was -422.7%, net loss $20.5M (377.5% of revenue).
Abeona Therapeutics, Q4 2025: revenue $5.4M, operating margin -422.7%, net loss $20.5M, operating cash flow −$18.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.4M | — | — |
| Operating profit | −$22.9M | — | — |
| Net earnings | −$20.5M | -119% | — |
| Operating cash flow | −$18.0M | — | — |
What changed
Revenue was $5.4M in Q4 2025.
Operating costs exceeded revenue by $22.9M, an operating margin of -422.7%. The quarter ended with a net loss of $20.5M.
Operating cash flow was −$18.0M. Non-cash charges added back $863K of depreciation and amortization and $2.6M of share-based compensation. Working capital and other items used $915K. Capital expenditures of $1.2M exceeded it, leaving free cash flow of −$19.1M.
Questions
What was Abeona Therapeutics' revenue in the fourth quarter 2025?
Abeona Therapeutics (ABEO) reported revenue of $5.4M for the fourth quarter 2025 (Q4 2025).
Was Abeona Therapeutics profitable in the fourth quarter 2025?
Operating loss was $22.9M (-422.7% of revenue) and net loss $20.5M.